Resalis Therapeutics develops RNA-based therapies aimed at treating the root causes of complex metabolic disorders. Its lead candidate, RES-010, is a first-in-class antisense oligonucleotide that targets miR-22 to reprogram metabolic pathways. The company reports robust preclinical data suggesting potential for sustained, high-quality weight loss and reductions in visceral and hepatic fat. Resalis says RES-010 could complement existing anti-obesity drugs such as GLP-1 receptor agonists by addressing underlying biology. The company is preparing to initiate a Phase 1 clinical trial and intends to use new proceeds to accelerate advancement through a Phase 2 proof-of-concept study. Resalis is supported by investors including Claris Ventures, Sunstone Life Science Ventures and private investors from Italian Angels for Growth and Club degli Investitori. Resalis Therapeutics is developing RES-010, an antisense oligonucleotide that targets miR-22 to provide a disease-modifying approach to obesity. RES-010 is designed to reduce fat mass and extend treatment durability, including in combination with approved therapies such as GLP-1 receptor agonists. In preclinical proof-of-concept studies in large and small animal models, RES-010 showed potential for safe and longer-lasting therapeutic effects. The company highlights preservation of muscle mass as important for sustained clinical benefit and tolerability. RES-010 is patent-protected in the US, Japan and China, with patents pending in the EU. Resalis plans to initiate a Phase 1 clinical study in the first half of 2024 and to use proceeds to reach Phase 2 readiness. Resalis Therapeutics is developing a non-coding RNA (ncRNA) modality targeting miR-22 to treat metabolic diseases such as obesity and nonalcoholic fatty liver disease (NAFLD). Its lead candidate, RES-010, is an antisense oligonucleotide (ASO) inhibitor of miR-22 that showed promising proof-of-concept efficacy and durable effects in rodent and non-human primate studies. The company aims to finalize IND-enabling studies to support a first-in-human clinical trial planned for early 2024. Resalis emphasizes a disease-modifying approach intended to deliver durable weight loss and reduction of hepatic steatosis, alone or in combination with approved drugs. Leadership changes concurrent with the financing include the appointment of Alessandro Toniolo, PhD, as CEO, and board representation from Claris Ventures. The funding announced will accelerate development of RES-010 toward clinical entry.

Total raised

$22M

Funding rounds

3

Latest round

Series A

Latest activity

Jan 2024